Were Analysts Bearish Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) This Week?

June 21, 2018 - By Linda Rogers

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) LogoInvestors sentiment decreased to 1.15 in Q1 2018. Its down 0.19, from 1.34 in 2017Q4. It fall, as 39 investors sold Vertex Pharmaceuticals Incorporated shares while 189 reduced holdings. 76 funds opened positions while 186 raised stakes. 232.72 million shares or 0.10% more from 232.48 million shares in 2017Q4 were reported.
Bb&T Ltd Llc owns 7,956 shares or 0.01% of their US portfolio. 97,100 are held by Picton Mahoney Asset Mgmt. 7,043 were accumulated by Regions Fincl Corporation. Dorsey Wright & Assocs has 0.38% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Quantbot Tech L P reported 22,318 shares or 0.31% of all its holdings. Cap Intl Ltd Ca invested in 0.18% or 6,034 shares. Baldwin Brothers Ma reported 1,304 shares or 0.03% of all its holdings. Bridgeway Capital Mngmt has invested 0.09% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ithaka Group Ltd Com stated it has 54,923 shares or 1.5% of all its holdings. Brown Advisory owns 6,023 shares. California State Teachers Retirement Sys reported 401,563 shares or 0.14% of all its holdings. Australia-based Amp Capital Invsts Ltd has invested 0.14% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 1,930 are owned by Princeton Portfolio Strategies Gp Ltd Llc. Shell Asset Mngmt holds 0.08% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 23,477 shares. Fiera Cap Corporation has 2,299 shares.

Since January 2, 2018, it had 0 insider purchases, and 50 sales for $88.91 million activity. $116,511 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Graney Thomas. Bhatia Sangeeta N. sold 875 shares worth $133,044. Another trade for 2,330 shares valued at $379,976 was sold by Parini Michael. Silva Paul M sold $544,730 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday, February 20. Sachdev Amit sold $736,800 worth of stock. Shares for $1.52 million were sold by Arbuckle Stuart A on Wednesday, January 24.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 18 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 18 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vertex Pharmaceuticals had 23 analyst reports since January 2, 2018 according to SRatingsIntel. The company was maintained on Tuesday, March 13 by Cowen & Co. Leerink Swann maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, February 1 with “Buy” rating. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Outperform” rating given on Tuesday, February 13 by Credit Suisse. The firm has “Buy” rating by Bank of America given on Friday, January 5. Jefferies maintained the stock with “Buy” rating in Wednesday, January 31 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Oppenheimer on Thursday, February 1. The rating was maintained by JMP Securities with “Market Outperform” on Tuesday, February 13. The rating was maintained by Morgan Stanley on Friday, April 27 with “Overweight”. BMO Capital Markets maintained it with “Buy” rating and $191.0 target in Thursday, February 1 report. The company was maintained on Tuesday, January 2 by BMO Capital Markets. Below is a list of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) latest ratings and price target changes.

27/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $200 New Target: $207 Maintain
27/04/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0000 Maintain
04/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $199.0000 Maintain
13/03/2018 Broker: Cowen & Co Rating: Buy New Target: $200.0 Maintain
05/03/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $195 New Target: $200 Maintain
23/02/2018 Broker: Argus Research Rating: Buy New Target: $194.0
13/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $200 New Target: $211 Maintain
13/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $195 New Target: $196 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $198 New Target: $200 Maintain
01/02/2018 Broker: Oppenheimer Rating: Buy New Target: $190.0 Upgrade

The stock decreased 0.66% or $1.04 during the last trading session, reaching $156.59. About 520,860 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 32.80% since June 21, 2017 and is uptrending. It has outperformed by 20.23% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.90 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 177.14 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Fool.com which released: “5 Experimental New Drugs That Could Be Worth $47 Billion” on June 20, 2018, also Nasdaq.com with their article: “Buy These 2 Biotech Stocks on the Dip After an FDA Delay” published on June 05, 2018, Fool.com published: “2 High-Flying Biotech Stocks With Even More Room to Grow” on June 20, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Streetinsider.com and their article: “Vertex Pharma (VRTX) Announces Access Agreement in Sweden for CF Medicine ORKAMBI” published on June 18, 2018 as well as Investorplace.com‘s news article titled: “After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall” with publication date: June 05, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: